PrEPTECH, a YTH online program and research study, is an integrated tech approach to increasing pre-exposure prophylaxis (PrEP) uptake among young gay and bi men. In 2012, the US Food and Drug Administration approval of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis to prevent HIV infection in high-risk individuals, offered a unique opportunity to curb the rising incidence of HIV infection in high-risk groups, particularly among YMSM.
Working closely with the community, YTH co-designed the PrEPTECH online web program to support the uptake and adherence of PrEP, while allowing users to bypass many of the barriers related to stigma, discrimination, and access. The current study aims to evaluate the PrEPTECH online program, and provide important PrEP access and care to a variety of community members.
For more information about the PrEPTECH program or research study, please contact [email protected].